Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non–Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study-Reference-Cited by-同舟云学术

Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non–Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study

Published:2016-08 Issue:2 Volume:70 Page:341-347
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Marttila Timo,Järvinen Riikka,Liukkonen Tapani,Rintala Erkki,Boström Peter,Seppänen Marjo,Tammela Teuvo,Hellström Pekka,Aaltomaa Sirpa,Leskinen Markku,Raitanen Mika,Kaasinen Eero

Publisher

Elsevier BV

Subject

Urology

Reference22 articles.

1. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013;Babjuk;Eur Urol,2013

2. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000

3. Maintenance bacillus Calmette-Guérin treatment of non–muscle-invasive bladder cancer: a critical evaluation of the evidence;Ehdaie;Eur Urol,2013

4. Long-term Outcome of Patients with Frequently Recurrent Non–muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 Study

5. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder: a Southwest Oncology Group study;Lamm;Urol Oncol,1995

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential benefits of concomitant statins treatment in patients with non‐muscle‐invasive bladder cancer;BJU International;2024-09-10

2. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

3. Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review;Journal of Clinical Medicine;2024-06-27

4. Metabolomic Signatures of Treatment Response in Bladder Cancer;International Journal of Molecular Sciences;2023-12-16

5. Research progress in the off-target effects of Bacille Calmette–Guérin vaccine;Chinese Medical Journal;2023-12-13